Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

Arie R Gafson; Xiaotong Jiang; Changyu Shen; Raj Kapoor; Henrik Zetterberg; Robert J Fox; Shibeshih Belachew

doi:10.1001/jamanetworkopen.2021.47588

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

JAMA Netw Open. 2022 Feb 1;5(2):e2147588. doi: 10.1001/jamanetworkopen.2021.47588.

Authors

Arie R Gafson¹, Xiaotong Jiang¹, Changyu Shen¹, Raj Kapoor², Henrik Zetterberg³, Robert J Fox⁴, Shibeshih Belachew¹

Affiliations

¹ Biogen Digital Health, Biogen, Cambridge, Massachusetts.
² Department of Neuroinflammation, University College London Queen Square Institute of Neurology, London, United Kingdom.
³ Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom.
⁴ Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio.

Abstract

This cohort study investigates serum neurofilament light concentration as a biomarker associated with disability progression in multiple sclerosis in the absence of acute inflammation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Biomarkers / blood*
Disease Progression
Female
Humans
Inflammation / blood
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis / blood*
Neurofilament Proteins / blood*

Substances

Biomarkers
Neurofilament Proteins